Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNT001 in WAIHA
NCT03075878Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of orilanolimab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Alexion Pharmaceuticals. Started Jan 2018; status: terminated.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT03075878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075878.